Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Random, Double-Blind, Multicenter, Positive Control and Placebo Control Phase Two Trail to Evaluate the Safety and Immunogenicity of Live Attenuated Influenza Vaccine in 3-59y Healthy People

NCT05284851 is registered in ClinicalTrials.gov with Changchun BCHT Biotechnology Co. as lead sponsor.

NCT NCT05284851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05284851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Random, Double-Blind, Multicenter, Positive Control and Placebo Control Phase Two Trail to Evaluate the Safety and Immunogenicity of Live Attenuated Influenza Vaccine in 3-59y Healthy People
Lead sponsor
Changchun BCHT Biotechnology Co.
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2022
Completion date
October 1, 2022
Enrollment
2,520 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza prevention